Introduction
Cervical cancer is the second most common malignancy in women worldwide. The overall survival rate of cervical cancer patients is 40% (Brinton, 1992; Grenlee et al., 2001) in spite of advances in chemotherapy and radiation procedures (Rose and Eifel, 2000) . Thus, the low levels of survival rates argue strongly for the development of novel therapies. The most important risk factor for cervical cancer is human papilloma virus (HPV) infection. Over 90% of all cervical cancers have been found to be positive for HPV (Lungu et al., 1995; Qu et al., 1997) . Several experimental evidences indicate that the E6 and E7 oncogenes of HPV play major roles in the development as well as in the maintenance of the malignant phenotype of cervical carcinoma. E6 and E7 of HPV 16 target the two major tumor suppressor proteins, p53 and retinoblastoma (Rb), respectively, in cervical cells (Scheffner et al., 1991) . E6 protein forms a complex with p53 (Storey et al., 1998) and abrogates p53 function of transcriptional activation by stimulating its degradation via ubiquitin-mediated proteolysis in an E6-associated protein (E6AP)-mediated reaction (Lechner and Laminis, 1994; BeerRomero et al., 1997) .
A variety of gene-based approaches have been developed for the treatment of cervical cancer. Although the introduction of p53 gene via an adenovirus carrying p53 has been shown to inhibit cervical cancer-derived cells (Hamada et al., 1996) , HPV E6-expressing cancer cells are relatively resistant to tumor-suppressive effects of exogenous wild-type p53 (Prabhu et al., 1996) . The p53-homologue p73 has been shown to perform similar functions to p53 in transcriptional activation and apoptosis (Jost et al., 1997; Kaghad et al., 1997) . Moreover, p73, unlike p53, is resistant to degradation by HPV 16 E6 and can suppress growth and induce apoptosis in HPV 16 E6-expressing cells (Prabhu et al., 1998) . Subsequently, it was found that the products of viral oncogenes adenovirus E1B, SV40T antigen and HPV E6 do not physically interact with p73 (Marin et al., 1998) . The fact that p73 is able to inhibit the growth of cells in the presence of HPV E6 raises the possibility that p73 could be a suitable alternate candidate for gene therapy of cervical cancer.
In this study, we have developed a replicationdeficient recombinant adenovirus expressing p73b (Ad-p73). p73 expressed from Ad-p73 induces growth arrest by increasing the levels of p21 WAF1/CIP1 and apoptosis in many cancer cell types. More importantly, we show that Ad-p73 but not Ad-p53 inhibited more efficiently the growth of HPV E6-expressing cancer cell lines of three different types as well as HeLa cells, which is a cervical cancer-derived cell line. Based on the results, we suggest that p73-expressing adenovirus (Ad-p73) could be a potential reagent for treating cervical cancer.
Results

Expression of p73 and p21
WAF1/CIP1 proteins in Ad-p73-infected cells
We have generated an Ad-p73 as described in Materials and methods section. To detect the expression of p73 protein in Ad-p73-infected cells, SW480 cells were infected at a multiplicity of infection (MOI) of 20 with Ad-p73 or the control virus Ad-LacZ. At 24 h after infection, the cells were fixed and stained for p73 protein. WAF1/CIP1 is time dependent (Figure 1c ). These results suggest that a functional p73 is expressed from Ad-p73.
Ad-p73 infection induces cell cycle arrest and apoptosis
Exogenous expression of p73 has been shown to induce growth arrest and apoptosis (Jost et al., 1997; Kaghad et al., 1997) . In order to see the effect of p73 expressed from Ad-p73 on cell cycle, we tested the extent of cellular DNA synthesis and cell cycle profile in Ad-p73-infected cells. The cellular DNA synthesis was monitored by measuring Brdu incorporation and In addition to the inhibition of DNA synthesis, FACS also reveals the induction of apoptosis in Ad-p73-infected cells (Figure 3a) . Cells with less than 2N content of DNA, which represent apoptotic cells, appeared in very high proportion by 48 h in Ad-p73-infected cells in comparison to Ad-LacZ-infected cells (35.1 vs 4.5%). Induction of apoptosis was also confirmed by poly-(ADP-ribose) polymerase (PARP) cleavage assay. PARP, an enzyme involved in DNA repair mechanisms, is cleaved by the caspase-3. Therefore, the cleavage of PARP from the native 116 to 85 kDa is considered as a hallmark of apoptosis. Ad-p73 infection but not AdLacZ infection resulted in the appearance of 85 kDa cleaved product of PARP by as early as 36 h after infection (Figure 3b , lane 5). In addition, nuclear fragmentation during apoptosis was also monitored by staining the cells with DAPI and visualizing them by fluorescence microscopy ( Figure 3c ). Ad-p73-infected SW480 (panel b), H460 (panel d) and H1299 (panel f) cells show bright blue fluorescence, which is indicative of nuclear fragmentation in comparison to Ad-LacZinfected cells. The induction of apoptosis in response to p73 overexpression occurs by 48 h as seen by flow cytometry data ( Figure 3a ) and DAPI staining (Figure 3c ). PARP cleavage assay suggests that the apoptosis induction occurs as early as by 36 h (Figure 3b ) of p73 overexpression. Taken together, the above results suggest that the infection of cells with Ad-p73 results in the induction of growth arrest and apoptosis.
Ad-p73 inhibits the growth of cancer cells
To assay the cytotoxicity of the Ad-p73, the ability of Ad-p73 to inhibit the growth of three different cell lines, which differ in their p53 status, was analysed. H460, a human lung carcinoma cell line (harbors WT p53); SW480, a human colon carcinoma cell line (harbors mutant p53); and Saos-2, a human osteosarcoma cell line (has both p53 alleles deleted) were used. Cells were infected with varying MOI of Ad-p73 and the cytotoxicity was analysed by MTT assay (Figure 4 ). Ad-p73 inhibited the growth of all the three cell lines very efficiently in comparison to Ad-LacZ (Figure 4a-c) . These results suggest that Ad-p73 is a potent inhibitor of cancer cell growth.
Ad-p73 is more potent than Ad-p53 in inhibiting proliferation of HPV 16 E6-expressing cells and HeLa cells p73 is resistant to degradation by HPV E6 and can suppress the growth and induce apoptosis in HPV E6-expressing cells (Prabhu et al., 1998) . In order to check whether Ad-p73 could inhibit the cancer cells carrying HPV E6, we used HPV E6 stable transfectants of three different cancer cell types carrying wild-type p53. HPV E6 stable transfectants of H460, HCT116 and U2OS were used. The same cell lines transfected with empty vector (denoted as NEO) were used as control cells. In addition, we also used HeLa cell line, which is derived from cervical cancer. HCT116 p53
À/À (a derivative of HCT116 wt), which carries deletion of both alleles of p53 (Bunz et al., 1998) , was used as a control. First, we verified the p53 status of all NEO and E6 clones. Both (deleted for both copies of p53) showed induction of p53 upon adriamycin treatment ( Figure 5 ). The inability of HPV E6 stable clones to stabilize p53 in response to adriamycin treatment suggests that p53 is degraded in E6 stable lines and they could be used for Ad-p73 cytotoxicity studies.
Next, we checked the ability of Ad-p73 to inhibit the growth of HPV E6-expressing cells and cervical cancerderived HeLa cells. The NEO and E6 versions were infected with different MOI of Ad-p73, Ad-p53 and the control virus Ad-LacZ and the cytotoxicity was measured by MTT assay (Figure 6 ). H460 NEO, HCT116 NEO and U2OS NEO cells were inhibited by both Ad-p53 and Ad-p73 viruses in comparison to AdLacZ virus (Figure 6a, c and e) . However, H460 E6, HCT116 E6 and U2OS E6 cells were inhibited by Adp73 very efficiently but not by Ad-p53 in comparison to Ad-LacZ (Figure 6b, d and f) . Similarly, the cervical cancer-derived cell line HeLa is also growth inhibited by Ad-p73 very efficiently but not by Ad-p53 (Figure 7 ). The control cell lines HCT116 wt and HCT116 p53 À/À were inhibited by both Ad-p73 and Ad-p53 very efficiently (Figure 6g and h) . These results suggest that Ad-p73 inhibits the growth of HPV E6-expressing cancer cells as well as cervical cancer-derived cells very efficiently.
The above results suggest that Ad-p73 but not Ad-p53 is able to inhibit the growth of cells expressing HPV E6 gene very efficiently. The inability of Ad-p53 to inhibit HPV E6-expressing cells could be attributed to the presence of E6, the product of which binds to p53 that leads to ubiquitin-mediated proteolysis of p53 (Lechner and Laminis, 1994; Storey et al., 1998) . On the contrary, the efficient inhibition of HPV E6-expressing cells by Ad-p73 could be attributed to the fact that p73 does not bind to HPV E6 and is also resistant to HPV E6-mediated degradation (Marin et al., 1998; Prabhu et al., 1998) . In order to confirm these facts, we checked the stability of p53 and p73 expressed from adenovirus in HPV E6-expressing cells and HeLa cells. Increased level of p53 upon Ad-p53 is seen only in H460 NEO, HCT116 NEO and U2OS NEO cells (Figure 8a) . Similarly, HCT116 wt as well as HCT116 p53 À/À cells showed increased levels of p53 upon Ad-p53 infection (Figure 8a ). However, H460 E6, HCT116 E6 and U2OS E6 cells as well as HeLa cells do not show any appreciable increase in p53 levels upon Ad-p53 virus infection. This explains why Ad-Ad-p53 is unable to inhibit the growth of HPV E6-expressing cells as well as HeLa cells. However, p73 expressed from Ad-p73 was stable in all cell lines tested (Figure 8b ). Both NEO and E6 transfectants of all the three cell lines showed similar levels of induced p73 upon Ad-p73 infection (Figure 8b) . Similarly, p73 is also stable in cervical cancer-derived cell line HeLa (Figure 8b ). In addition, the p73 expressed from Ad-p73 in E6-expressing cells is also functional as seen by the fact that p73 induced p21 WAF1/CIP1 with a similar efficiency in E6 and NEO stable cell lines (Figure 8b ). These results confirm that p73 but not p53 expressed from a recombinant adenovirus is stable and functional in the presence of HPV E6 protein.
Discussion
Our study shows that Ad-p73 could be used to inhibit the growth of cancer cells derived from cervical cancer. We have developed a replication-deficient adenovirus carrying p73b, which expresses functional p73 protein.
Ad-p73 inhibited the growth of many cancer cells particularly HPV E6-expressing cells as well as HeLa cells, which are derived from cervical cancer. However, Ad-p53 failed to inhibit the growth of HPV E6-expressing cells as well as HeLa cells efficiently under similar conditions. The inability of Ad-p53 to inhibit HPV E6-expressing cells is found to Adriamycin  --+  -+  -+  -+  -+  -+  -+  -+  -+   p53   Actin   SW480  H460 NEO  H460 E6  HCT116 NEO  HCT116 E6  HCT116 wt  HCT116 p53 -/-U20S NEO  U20S E6 HeLa Figure 5 p53 is not stabilized in response to DNA damage in HPV E6-expressing cells: indicated cells were treated with adriamycin for 24 h. The total cell extracts were subjected to Western analysis for p53 and actin proteins as described in Materials and methods p73 gene therapy against cervical cancer S Das et al be due to the fact that p53 is not stable in the presence of HPV E6 (Figure 8a ). The tumor suppressor p53 is a potent growth inhibitor because it is able to inhibit growth by inhibiting cell cycle progression as well as inducing apoptosis. Mutations in p53 have been observed in approximately 50% of most human primary tumors (Hollstein et al., 1991; Levine, 1997) . Inactivation of p53 not only results in the development of tumor, it also results in chemoresistance in many types of cancer. Therefore, introducing wild-type p53 back into tumor cells results in the activation of growth inhibitory pathways, which makes tumor cells sensitive to chemotherapeutic drugs. For these reasons, p53-based gene therapy has been found very effective against several types of cancer. However, p53-based gene therapy is not effective in certain conditions. Amplification of mdm-2 (Oliner et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997) or mutational inactivation of p14 ARF (Kamijo et al., 1998; Stott et al., 1998; Zhang et al., 1998; Orlow et al., 1999) renders p53 pathway of growth suppression inactive. Similarly, cervical cancer-derived cells are resistant to p53-mediated growth suppression, which is due to the fact that the product of HPV oncogene E6 binds to p53 leading to the degradation of p53 through ubiquitination (Prabhu et al., 1996) .
Several alternate candidate genes or methodologies have been attempted for treatment of cervical cancer. The proapoptotic gene bax, introduced through an adenovirus, is found to be effective in inducing apoptosis in cervical cancer-derived cells (Huh et al., 2001) . The universal cdk inhibitor p21 WAF1/CIP1 , expressed from an adenovirus, has been found to be very effective in inhibiting the growth of cancer cells expressing HPV E6 gene or human cervical cancerderived cancer cell lines (Prabhu et al., 1998; Tsao et al., 1999) . Antisense approach against HPV E6/E7 oncogene or telomerase RNA has been found to be effective in inhibiting the growth of cervical cancer cells (Hamada et al., 1996; Yatabe et al., 2002) . We have attempted p73-based approach for efficient inhibition of growth of cervical cancer cells. The basis for this study came from the fact that p73 does not bind to HPV E6 (Marin et al., 1998) and is stable in the presence of HPV E6 gene (Prabhu et al., 1998) . In addition, p73 also inhibited the growth of cancer cells expressing HPV E6 oncogene very efficiently unlike p53 (Prabhu et al., 1998) . In our study, p73 expressed from an adenovirus efficiently inhibited the growth of three different cancer cell lines expressing HPV E6 oncoegne ( Figure 6 ). In addition, p73 also inhibited the growth of HeLa cells, which are derived from cervical cancer (Figure 7 ). The ability of p73 expressed from adenovirus to inhibit HPV E6-expressing cells was found to be due to the stable expression of p73 in those cells (Figure 8b ). However, p53 expressed from an adenovirus failed to inhibit HPV E6-expressing cells efficiently, which correlated with the fact that p53 was not stable in E6-expressing cells (Figure 8a ). These results suggest that Ad-p73-based approach could be a potential gene therapy strategy for cervical cancer.
Materials and methods
Plasmids pCDNA3-p73b is described before (Prabhu et al., 1998) . pAdTrack-CMV and pAdEasy-1, described previously (He et al., 1998) , were provided by Dr Bert Vogelstein, Johns Hopkins University.
Tumor cell lines and culture conditions
Human cancer cell lines 293, SW480, H460, Saos-2, HeLa and HCT116 wt were described previously Somasundaram et al., 1999) . The human lung carcinoma cell line H1299 carries a homozygous deletion of p53 and was kindly provided by Dr Tapas Kumar Kundu, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India. HCT116 p53
, which lacks both copies of p53, was kindly provided by Dr Bert Vogelstein, Johns Hopkins University (Bunz et al., 1998) . H460 NEO, H460 E6, HCT116 NEO, HCT116 E6, U20S NEO and U2OS E6 were described previously Prabhu et al., 1998; Takimoto et al., 2002) . NEO or E6 stable cell lines were made by transfecting pCMV-Neo or E6 (derived from HPV 16) construct followed by selection for G418 resistance. Transfections into 293 cells were carried out by using the calcium phosphate method (Somasundaram et al., 1996) .
Adenovirus reagents and infections
The following adenoviruses were used in this study: Ad-LacZ lacks both E1A and E1B but carries b-galactosidase (El-Deiry et al., 1993) . Ad-p73 lacks both E1A and E1B but carries simian p73b. It was constructed using a procedure described previously (He et al., 1998) . Briefly, p73b was cloned as a HindIII/XbaI fragment from pCDNA3-p73b into pAdTrack-CMV. pAdTrack-CMV-p73b was linearized with PmeI and cotransformed along with pAdEasy-1 into Escherichia coli BJ5183 selecting for kanamycin resistance. Clones carrying appropriate recombinant plasmid were identified, plasmid DNA extracted, linearized with PacI and tranfected into 293 cells. The recombinant virus plaques were identified as localized areas of clearing consisting of round cells, which fluoresce green under fluorescent microscopy. Adenoviral infections were carried out as described .
Western and immunohistochemical analysis
Western analysis and immunohistochemical staining were performed as described before ) with mouse anti-human p21 WAF1/CIP1 (Ab-1; Oncogene), mouse anti-human p73 monoclonal (Ab-2; Oncogene), mouse anti-human p53 monoclonal (Ab-2; Oncogene), mouse antihuman Rb monoclonal (LM95.1 clone; Ab5; Oncogene), mouse anti-human PARP monoclonal (Ab-2; Oncogene) and goat anti-human actin polyclonal (I-19; Santa Cruz). Cells were harvested or fixed at 24 h or appropriate time points as described after virus infection and subjected to analysis. 
